PITPNM3

Across TCGA pan-cancer cohorts, PITPNM3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PITPNM3 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PITPNM3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PITPNM3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LIHC, ESCA, and LUAD are the cancer types where PITPNM3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.107	0.557	<.001	24	view →
ESCA	OS	Median	All	0.275	0.704	.007	6	view →
LUAD	OS	Median	II,III,IV	0.163	0.749	.010	6	view →
UCEC	DFS	Median	All	0.957	0.627	.028	4	view →
BLCA	OS	Median	IV	0.510	0.284	.014	4	view →
STAD	DFS	Median	III,IV	0.696	0.331	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PITPNM3–LIHC (DFS)

Open the LIHC breakdown →